Overview

AZD5672 Bioavailability Study in Healthy Male and Female Subjects

Status:
Completed

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to compare the blood levels achieved with a new formulation of AZD5672 to an existing formulation of AZD5672 used in previous studies

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide